|
Original Research Article
Long-Term Effect of HAART
on Biochemical Profiles of HIV/AIDS Patients in a
Tertiary Health Facility in Benin City, Nigeria
Shakirat I Bello1,3,
Abel N Onunu2, and Patrick O Erah4*
1Department of Clinical
Pharmacy and Pharmacy Practice, Faculty of
Pharmaceutical Sciences, University of Ilorin, Ilorin,
2Department of Internal Medicine, University
of Benin Teaching Hospital, 3Department of
Clinical Pharmacy & Pharmacy Practice, and 4Pharmacotherapy
Group, Faculty of Pharmacy, University of Benin, Benin
City, Nigeria
*For correspondence:
Email:
patrick.erah@uniben.edu; Tel:
+234-805-526-3622
Received: 8 July 2014
Revised accepted: 11
October 2014
Tropical
Journal of Pharmaceutical Research, November 2014;
13(11): 1 941-1946
http://dx.doi.org/10.4314/tjpr.v13i11.24
Abstract
Purpose: To assess the long-term
effect of highly active antiretroviral therapy (HAART)
on biochemical parameters of HIV-infected patients in
University of Benin Teaching Hospital (UBTH), Benin
City, Nigeria.
Methods: HIV/AIDS patients on HAART
for 2 - 8 years (297), those who were not on HAART (112,
positive control), and healthy subjects (103, negative
control) were recruited in the Infectious Diseases
Clinic (IDC) of UBTH. Their sera were assayed for
biochemical parameters. WHOQoL bref instrument was used
to assess patients’ Quality of life (QoL).
Results: Patients who have been on
HAART had significantly elevated ALT and AST levels (p <
0.001) but mild liver toxicity. QoL of these patients
was not significantly different from that of the healthy
controls. The levels of Na+ (133.4 ± 5.2 mmol/l),
K+ (3.6 ± 0.4 mmol/l) and Cl-
(101.3 ± 4.0 mmol/l) were significantly lower in
patients on HAART than those of the positive (137.5 ±
5.1, 3.9 ± 0.5, 104.3 ± 5.7 mmol/l respectively, p <
0.001). Also, levels of creatinine (0.8 ± 0.2 mg/dl),
TBil (0.5 ± 0.2 mg/dl), and CB (0.3 ± 0.5 mg/dl) were
significantly higher in patients on HAART than those of
either the positive (0.7 ± 0.3, 0.4 ± 0.2, 0.2 ± 0.1
mg/dl) or negative (0.7 ± 0.3, 0.3 ± 0.1, 0.2 ± 0.1
mg/dl) controls respectively (p < 0.001).
Conclusion: Treatment with HAART for 2
- 8 years may not produce severe hepatotoxicity in
HIV/AIDS patient though mild liver toxicity should be
expected. The patients’ QoL was not negatively affected
by the use of HAART for 2 - 8 years.
Keywords: Biochemical parameters,
HIV/AIDS, Long-term HAART, Quality of life (QoL). |